The greatest unknown if which reimbursement model for these high-cost therapies will gain supremacy, explained Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology.
The greatest unknown if which reimbursement model for these high-cost therapies will gain supremacy, explained Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology.
TranscriptWhat do you see in the future for reimbursement for high-cost therapies?
I think that the greatest unknown in this, and I think there are a lot of unknowns, is which model will gain supremacy. So, if I had to bet, I think there’s definitely going to be a performance-based aspect of it. Whether its shorter or long term, it’s still unclear because of the complexities of managing this over the longer term. I think there’s opportunities for new players like third-party administrators to help with some of the data capture and looking at people’s movement between plans and their outcomes if they leave a plan.
I think providers will have a piece in that, in monitoring patients and getting reimbursed for monitoring patients’ outcomes in ways maybe that they haven’t always had good reimbursement in the past. And then, the greatest unknown is the aggregate effect of all these new therapies as they gain approval. I think there’s dozens of therapies that potentially could be approved between now and 2025. One is the number of therapies and the other piece is the number of patients who are eligible and that total cost that will potentially be on the table. Whether people can bear that in the short term or need to move to new models is still unknown and a lot will play out as the approvals move forward.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen